[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Seoul St. Mary's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":130},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,77,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100611458","phase-4-enavogliflozin-for-the-management-of-patients-with-amyloid-cardiomyopathy-100611458",false,"NCT07240844","Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy","Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy - A Randomized, Double-Blind, Placebo-Controlled, Crossover, Multicenter Trial","EMPACT","Inclusion Criteria:\n\n1. Adults aged 19 years or older\n2. Diagnosed with amyloid cardiomyopathy confirmed by cardiac biopsy or non-invasive imaging\n3. Presence of heart failure symptoms corresponding to NYHA functional class II-III\n4. Patients on stable oral diuretic use, without dose changes exceeding 50% of the previous dose, for at least 2 weeks prior to study enrollment\n5. Ambulatory (able to walk)\n6. Able to provide written informed consent for study participation\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women\n2. Active infection\n3. Major cardiovascular events (e.g., myocardial infarction, stroke) within the past 6 months\n4. Scheduled for coronary revascularization, CRT-D implantation, atrial flutter\u002Ffibrillation ablation, or valve surgery\n5. History of heart transplantation\n6. Estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m² (calculated by CKD-EPI formula)\n7. No history of cancer within the past 5 years at screening (except borderline cancers without recurrence for 2-3 years; multiple myeloma with cardiac involvement is classified as cardiac amyloidosis and is exempt)\n8. Heart failure primarily caused by severe left sided valvular disease or ischemic heart disease (except if valvular disease is corrected)\n9. Type 1 diabetes mellitus or insulin-dependent diabetes\n10. History of ketoacidosis, complicated urinary or genital infections, or kidney stones\n11. Systolic blood pressure \\\u003C 80 mmHg or symptomatic hypotension\n12. Major surgery within 90 days prior to enrollment\n13. Known hypersensitivity or allergic reaction to the study drug or its components\n14. Moderate to severe liver impairment\n15. Chronic alcohol or substance abuse\n16. Residing in long-term care facilities (e.g., nursing homes)\n17. Unable to understand or comply with study drug, procedures, or follow-up, or who are deemed by the investigator to be unlikely to complete the study","ALL","19 Years",{"count":20,"type":21},68,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.",[27],"Amyloid Cardiomyopathy",[27,29,30],"Enavogliflozin","Sodium-Glucose Cotransporter 2 Inhibitor","RECRUITING","2026-06-16",{"date":34,"type":35},"2026-06-18","ACTUAL",{"date":37,"type":35},"2026-01-06",{"date":39,"type":21},"2027-05-31",{"name":41,"class":42},"Seoul St. Mary's Hospital","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100643143","prediction-of-atrial-fibrillation-using-polygenic-risk-score-100643143","NCT07641582","Prediction of Atrial Fibrillation Using Polygenic Risk Score","Development of an Atrial Fibrillation Prediction Model Using Polygenic Risk Score: A Prospective Cohort Study","PREGENCE","Inclusion Criteria:\n\n* Patients with symptoms suggestive of paroxysmal atrial fibrillation, such as intermittent palpitations or chest discomfort\n* Asymptomatic patients aged 60 or older with at least one of the following risk factors for atrial fibrillation: hypertension, diabetes, coronary artery disease, valvular heart disease, cardiomyopathy, sleep apnea, hyperthyroidism, obesity (BMI greater than 30), or chronic alcohol dependence (drinking more than 3 times per week)\n\nExclusion Criteria:\n\n* Age under 20 years or over 80 years\n* Moderate or severe cognitive impairment\n* Previously diagnosed with atrial fibrillation prior to study enrollment\n* Does not consent to participate in the study","20 Years","79 Years",{"count":55,"type":21},800,[57],"NA","The goal of this clinical trial is to learn whether a genetic risk score can help identify undiagnosed atrial fibrillation (AF) in adults who may have it. AF is an irregular heartbeat that raises the risk of stroke if not treated early.\n\nThe main questions it aims to answer are:\n\nCan a polygenic risk score (PRS) - a score based on a person's genes - identify who is more likely to have AF? Does combining PRS with a person's medical history predict AF better than using medical history alone?\n\nParticipants will:\n\nWear a continuous ECG patch for 7 days to record heart rhythm Give a blood sample for genetic testing to calculate their PRS Use a six-lead handheld ECG device (HATIV® P30, VUNO Inc., Seoul, Republic of Korea) to check their own heart rhythm at home once or twice a week for 1 year Visit the clinic 5 times over 1 year\n\nResearchers will use the genetic and clinical information collected to build a scoring system that predicts who is at risk for AF.",[60],"Atrial Fibrillation (AF)",[62,63,64,65,66,67],"Polygenic Risk Score","Atrial Fibrillation Screening","Handheld ECG","SNP Array","Holter Monitoring","Genetic Risk","2026-06-06",{"date":70,"type":35},"2026-06-11",{"date":72,"type":35},"2024-11-19",{"date":74,"type":21},"2027-06-30",{"name":41,"class":42},5,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":52,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100619469","acellular-dermal-matrixsurederm-bcs-in-breast-conserving-surgery-for-breast-cancer-patients-100619469","NCT07345026","Acellular Dermal Matrix(SureDerm BCS) in Breast-Conserving Surgery for Breast Cancer Patients","Clinical Efficacy of Acellular Dermal Matrix (Product Name: SureDerm BCS) in Breast Cancer Patients Undergoing Breast-Conserving Surgery","Inclusion Criteria:\n\n* Female patients aged 20 to 75 years\n* Diagnosed with unilateral breast cancer (ICD-10 code: C50, D05) and treated with breast-conserving surgery\n* Agreed to the use of acellular dermal matrix (ADM) during surgery\n* Histologically confirmed primary breast cancer\n* Patients who received neoadjuvant chemotherapy are eligible\n* Planned to receive standard postoperative treatment, including adjuvant radiotherapy\n* Voluntarily decided to participate in the study and provided written informed consent\n\nExclusion Criteria:\n\n* Evidence of distant metastasis\n* Presence of infectious disease, autoimmune disease (e.g., specific rheumatologic disorders), or bleeding\u002Fcoagulation disorders\n* Known adverse reactions to all first-line antibiotics\n* Suspected inflammatory infection of the breast prior to surgery\n* Pregnant women at the time of enrollment\n* Definite contraindications to the use of acellular dermal matrix\n* Contraindications to radiotherapy\n* Male patients\n* History of another malignancy diagnosed within the past 5 years\n* Patients deemed unsuitable for participation due to difficulty in data collection as judged by the investigator\n* Patients unable to understand or complete the study questionnaires","FEMALE","75 Years",{"count":87,"type":21},116,[57],"The goal of this clinical trial is to evaluate whether the use of an acellular dermal matrix (SureDerm) can improve cosmetic satisfaction and is safe in women with breast cancer undergoing breast-conserving surgery.\n\nThe main questions it aims to answer are:\n\n1. Does the use of SureDerm improve patient-reported cosmetic satisfaction after breast-conserving surgery?\n2. Is the use of SureDerm safe in terms of complication rates compared to standard surgery without SureDerm?\n\nResearchers will compare patients receiving SureDerm during surgery with patients undergoing standard breast-conserving surgery without SureDerm to see if cosmetic results and safety differ between the groups.\n\nParticipants will:\n\n* Undergo breast-conserving surgery, with or without SureDerm (assigned randomly)\n* Receive standard postoperative radiotherapy\n* Complete questionnaires about cosmetic satisfaction (Breast-Q) at baseline, 1 month, and 12 months after surgery\n* Be followed for complications and cosmetic assessments by physicians",[91,92],"Breast Neoplasms","Mastectomy, Segmental",[94,95,96,97],"Breast Cancer","Breast-Conserving Surgery","Acellular Dermal Matrix","Oncoplastic Surgery","NOT_YET_RECRUITING","2026-01-07",{"date":101,"type":35},"2026-01-15",{"date":103,"type":21},"2026-01-08",{"date":105,"type":21},"2028-04-30",{"name":41,"class":42},1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":107},"100551307","comparison-of-clinical-outcomes-according-to-high-protein-provision-in-critically-ill-patients-after-abdominal-surgery-100551307","NCT06458387","Comparison of Clinical Outcomes According to High-protein Provision in Critically Ill Patients After Abdominal Surgery","Comparison of Clinical Outcomes According to High-protein Provision Through Parenteral Nutrition in Critically Ill Patients Immediately After Abdominal Surgery: a Prospective, Single-blinded, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients admitted after abdominal surgery to our institution's surgical ICU\n* They were enrolled regardless of the surgical method, either open, laparoscopy, or robotic.\n\nExclusion Criteria:\n\n* aged under 18 years\n* underwent surgery under local or regional anesthesia\n* pregnant\n* readmitted to the ICU due to any cause\n* diagnosed with renal failure and receiving renal replacement therapy\n* patients diagnosed with multiorgan failure, represented by a high Sequential Organ Failure Assessment (SOFA) score (≥9) upon ICU admission\n* failed to provide informed consent, or with 'do-not-resuscitate' status.","18 Years",{"count":117,"type":21},152,[57],"Protein malnutrition in critically ill patients is a global concern due to its association with prolonged hospital stays, and higher morbidity rates. Patients who undergo abdominal surgery are particularly vulnerable due to alterations in gastrointestinal function and prolonged fasting. Despite the significance of proper nutrition, the optimal target of protein supplementation remains controversial.\n\nThe investigators aimed to evaluate the effects of high protein provision, targeting a protein intake of at least 1.5 g\u002Fkg\u002Fday for the first 3 days after abdominal surgery, on 6-month mortality.",[121],"Protein Malnutrition","2024-06-11",{"date":124,"type":35},"2024-06-13",{"date":126,"type":21},"2024-07",{"date":128,"type":21},"2027-06",{"name":41,"class":42},""]